A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin

Camillo F. Pollera, Mario Nardi, Paolo Marolla, Paolo Carlini

Research output: Contribution to journalArticle

Abstract

To evaluate the antiemetic effectiveness and toxicity of a novel congener of metoclopramide (MCP), alizapride (AZP), 29 patients receiving cisplatin (50 mg/m2) alone or with adriamycin (40 mg/m2) were entered into a randomized cross-over trial comparing moderate-dose AZP (2 mg/kg for 4 doses) administered alone or with dexamethasone (DXM) (8 mg for five doses) vs a standard combination of MCP (1 mg/kg for four doses) and DXM (as above). With the dosage and schedule used, AZP provided only limited antiemetic protection, with less than 10% of the patients free of emesis. The AZP-DXM combination was significantly more effective than AZP alone in reducing the intensity of the emesis (P

Original languageEnglish
Pages (from-to)335-338
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume19
Issue number4
DOIs
Publication statusPublished - Jul 1987

Fingerprint

Metoclopramide
Dexamethasone
Cisplatin
Vomiting
Antiemetics
Doxorubicin
Cross-Over Studies
Toxicity
Appointments and Schedules
alizapride

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin. / Pollera, Camillo F.; Nardi, Mario; Marolla, Paolo; Carlini, Paolo.

In: Cancer Chemotherapy and Pharmacology, Vol. 19, No. 4, 07.1987, p. 335-338.

Research output: Contribution to journalArticle

@article{1f5dedf668ab4c78b931284cc1c5514c,
title = "A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin",
abstract = "To evaluate the antiemetic effectiveness and toxicity of a novel congener of metoclopramide (MCP), alizapride (AZP), 29 patients receiving cisplatin (50 mg/m2) alone or with adriamycin (40 mg/m2) were entered into a randomized cross-over trial comparing moderate-dose AZP (2 mg/kg for 4 doses) administered alone or with dexamethasone (DXM) (8 mg for five doses) vs a standard combination of MCP (1 mg/kg for four doses) and DXM (as above). With the dosage and schedule used, AZP provided only limited antiemetic protection, with less than 10{\%} of the patients free of emesis. The AZP-DXM combination was significantly more effective than AZP alone in reducing the intensity of the emesis (P",
author = "Pollera, {Camillo F.} and Mario Nardi and Paolo Marolla and Paolo Carlini",
year = "1987",
month = "7",
doi = "10.1007/BF00261484",
language = "English",
volume = "19",
pages = "335--338",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin

AU - Pollera, Camillo F.

AU - Nardi, Mario

AU - Marolla, Paolo

AU - Carlini, Paolo

PY - 1987/7

Y1 - 1987/7

N2 - To evaluate the antiemetic effectiveness and toxicity of a novel congener of metoclopramide (MCP), alizapride (AZP), 29 patients receiving cisplatin (50 mg/m2) alone or with adriamycin (40 mg/m2) were entered into a randomized cross-over trial comparing moderate-dose AZP (2 mg/kg for 4 doses) administered alone or with dexamethasone (DXM) (8 mg for five doses) vs a standard combination of MCP (1 mg/kg for four doses) and DXM (as above). With the dosage and schedule used, AZP provided only limited antiemetic protection, with less than 10% of the patients free of emesis. The AZP-DXM combination was significantly more effective than AZP alone in reducing the intensity of the emesis (P

AB - To evaluate the antiemetic effectiveness and toxicity of a novel congener of metoclopramide (MCP), alizapride (AZP), 29 patients receiving cisplatin (50 mg/m2) alone or with adriamycin (40 mg/m2) were entered into a randomized cross-over trial comparing moderate-dose AZP (2 mg/kg for 4 doses) administered alone or with dexamethasone (DXM) (8 mg for five doses) vs a standard combination of MCP (1 mg/kg for four doses) and DXM (as above). With the dosage and schedule used, AZP provided only limited antiemetic protection, with less than 10% of the patients free of emesis. The AZP-DXM combination was significantly more effective than AZP alone in reducing the intensity of the emesis (P

UR - http://www.scopus.com/inward/record.url?scp=0023186763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023186763&partnerID=8YFLogxK

U2 - 10.1007/BF00261484

DO - 10.1007/BF00261484

M3 - Article

C2 - 3297376

AN - SCOPUS:0023186763

VL - 19

SP - 335

EP - 338

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -